Emerging drugs for complications of end-stage liver disease

Author： Dowman Joanna K   Holt Andrew P   Newsome Philip N   Adams David H  

Publisher： Informa Healthcare

ISSN： 1472-8214

Source： Expert Opinion on Emerging Drugs, Vol.13, Iss.1, 2008-03, pp. : 159-174

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Ropivacaine clearance is reduced in chronic end-stage liver disease

By  

Inpharma, Vol. 1, Iss. 1573, 2007-01 ,pp. : 19-19

Adis International

Access to resources Recommend Favorite

Epidemiology of end-stage renal disease

By Roderick Paul  

Clinical Medicine, Vol. 2, Iss. 3, 2002-05 ,pp. : 200-204

Royal College Of Physicians

Access to resources Recommend Favorite

New Management Options for End-Stage Chronic Liver Disease and Acute Liver Failure: Potential for Pediatric Patients

By Debray Dominique  

Pediatric Drugs, Vol. 8, Iss. 1, 2006-01 ,pp. : 1-13

Adis International

Access to resources Recommend Favorite

Emerging drugs for non-alcoholic fatty liver disease

By Federico Alessandro   Niosi Marco   Vecchio Blanco Camillo Del   Loguercio Carmela  

Expert Opinion on Emerging Drugs, Vol. 13, Iss. 1, 2008-03 ,pp. : 145-158

Informa Healthcare

Access to resources Recommend Favorite

Pharmacotherapy for end-stage coronary artery disease

By Sodha Neel R   Chu Louis M   Boodhwani Munir   Sellke Frank W  

Expert Opinion on Pharmacotherapy, Vol. 11, Iss. 2, 2010-02 ,pp. : 207-213

Informa Healthcare

Access to resources Recommend Favorite